Ultra-sensitive niche Exazym offers ultra-sensitive detection for low-abundance biomarkers within standard immunoassay workflows, presenting a clear value proposition for labs seeking higher assay sensitivity without overhauling existing processes.

Biomarker research focus Global use by biomedical scientists across basic, transitional, and pre-clinical biomarker research indicates opportunities to expand in academic collaborations, contract research, and early-stage biotech programs.

Growth potential Revenue is in the low single-to-mid range, and raised funding supports scale; target expansion through tiered offerings, service partnerships, and regional distributor networks to accelerate adoption.

HIV lineage fit Cavidi’s history with viral load solutions positions potential cross-sell opportunities into infectious disease diagnostics or HIV-related research programs, leveraging established credibility.

Quality and momentum ISO 9001 alignment and notable product launch momentum since 2021 provide a selling point for customers prioritizing quality systems, reliability, and proven technology integration within their workflows.